Adalimumab antibody | AbD18664_hIgG1

100% Secure

HCA205 specificity ELISA using various antigens as coating reagents. HRP conjugated Human anti-Adalimumab antibody (HCA205) was used as the detection reagent.
HCA205 Anti-Drug-Antibody (ADA) assay, bridging format. Adalimumab was used as the coating reagent followed by anti-Adalimumab antibodies in human IgG1 format (black squares HCA203; red circles HCA204; green triangles HCA205). Detection was performed with HRP conjugated Adalimumab.
Inhibition of Adalimumab binding to TNFα by HCA205. TNFα was used as the coating antigen followed by a pre-incubated mixture of Human anti Adalimumab (HCA205) titrated into a constant amount of Adalimumab. Free Adalimumab still capable of binding to the plate was detected using HRP conjugated HCA207 (Human anti Adalimumab-TNFα complex specific).

Human anti Adalimumab

Anti-adalimumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human immunoglobulin format; it is suitable as a reference standard in an immune response assay to measure anti-drug antibody levels for adalimumab or biosimilars.

Human anti Adalimumab, clone AbD18664_hIgG1, is an anti-idiotypic antibody that specifically recognizes the adalimumab monoclonal antibody and inhibits the binding of adalimumab to its target, TNFα. Clone AbD18664_hIgG1 can be used to measure the levels of adalimumab and biosimilar products using bioanalytical assays.

Adalimumab (branded as Humira®) is a fully human monoclonal antibody (IgG1/kappa) approved for the treatment of ankylosing spondylitis, Crohn’s disease, psoriasis and several forms of arthritis. The antibody is specific for TNFα, and acts by blocking the activation of TNF receptors by TNFα. This inactivation down-regulates the inflammatory reactions associated with autoimmune diseases.

Product Details

Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation

Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant

Buffer Solution

Phosphate buffered saline.

Preservative Stabilisers

0.01% Thiomersal

Immunogen

Adalimumab

Affinity

The monovalent intrinsic affinity of this antibody was measured as KD=10.5 nM by real time, label-free molecular interaction analysis on immobilized adalimumab.

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml.

Storage Information

Storage

Store at +4oC or at -20oC if preferred.Storage in frost-free freezers is not recommended.This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Shelf Life

12 months from date of despatch.

More Information

Acknowledgements

Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.Humira® is a registered trademark of Abbott Laboratories.

Licensed Use

For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory

For research purposes only

Applications of Adalimumab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

Application Name

Verified

Min Dilution

Max Dilution

ELISA

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

HCA205 specificity ELISA using various antigens as coating reagents. HRP conjugated Human anti-Adalimumab antibody (HCA205) was used as the detection reagent.
HCA205 Anti-Drug-Antibody (ADA) assay, bridging format. Adalimumab was used as the coating reagent followed by anti-Adalimumab antibodies in human IgG1 format (black squares HCA203; red circles HCA204; green triangles HCA205). Detection was performed with HRP conjugated Adalimumab.
Inhibition of Adalimumab binding to TNFα by HCA205. TNFα was used as the coating antigen followed by a pre-incubated mixture of Human anti Adalimumab (HCA205) titrated into a constant amount of Adalimumab. Free Adalimumab still capable of binding to the plate was detected using HRP conjugated HCA207 (Human anti Adalimumab-TNFα complex specific).